 Cybin Inc NYSE: CYBN, a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive pre-clinical data, indicating that its drug, CYB003 showed strong signs of cognitive improvement in patients with Major Depressive Disorder MDD. Cybin chemically engineered and developed CYB003 to address some of the shortcomings of oral psilocybin as a treatment for mental health, including slow onset, high variability and short duration of action. 